CORONAVIRUS (COVID-19): CHECK HERE FOR LATEST INFORMATION, NEWS AND MORE
BlueNet SPECIALITIES
Coronavirus (COVID-19)

Antibody Cocktail to Prevent COVID-19: Passive Vaccine?

Pharmaceutical Regeneron creates an antibody cocktail as an alternative to the COVID-19 vaccine

Antibody Cocktail to Prevent COVID-19: Passive Vaccine?

Regeneron Pharmaceuticals Inc has reported that its "REGEN-COV" antibody cocktail works to prevent COVID-19 in those exposed to those infected with the novel coronavirus; this information is supported by an advanced stage trial conducted.


Data has shown that the passive vaccine works, reducing symptomatic contagion by 100% and a 50% lower overall infection rate. The trial was conducted with about 400 participants who lived at home with someone infected with COVID-19.


Regeneron will discuss the interim results with US health regulators to distribute the current authorization for the emergency use of the antibody cocktail in the coming days.

It is estimated that the trial's information will be known at the beginning of the second trimester.


The current trial proved that REGEN-COV works as a passive vaccine; this includes the direct delivery of antibodies that fight the virus in the body, compared to traditional vaccines. The immune system of the recipient is activated to create its antibodies.

"Data using REGEN-COV as a passive vaccine propose that it can decrease virus infection and reduce disease and viral load in those who are still infected," said George Yancopoulos, Regeneron's President and Chief Scientific Officer.


Regeneron Pharmaceuticals Inc hopes that the REGEN-COV antibody cocktail can help people who do not have an excellent vaccination reaction.


In this trial, led jointly by Regeneron Pharmaceuticals Inc and the National Institute of Allergy and Infectious Diseases, one COVID-19-related death and hospitalization were reported among people who had received placebo no such incidents in the group. Treatment, the company said.


REGEN-COV is also working on two advanced-stage trials, one to treat hospitalized patients and treat out-of-hospital patients.

On the other hand, The New England Journal of Medicine, a medical journal, has published the results of clinical trials by Eli Lilly and Regeneron, which show encouraging and promising data. Eli Lilly and Regeneron are significantly expanding their studies to define the clinical benefits of their monoclonal antibodies, and Operation Warp Speed ​​and the National Institutes of Health plan to include several of these antibodies for treatment in their ACTIV-2 trial involving outpatients with COVID-19.

 

If these drugs are shown to offer reliable early treatment of COVID-19, they will significantly improve infection management. Such treatments are a logistical challenge but should inspire early and rapid rest for people at high risk for SARS-COV2 infection.

 

Interventions that prevent the progression of COVID-19 can be expected to reduce the morbidity and mortality from the infection, the frequency of hospitalizations, and the current excruciating strain on the US healthcare system.


Click here for more information.

 

BlueNetHospitals - Hospital Los Cabos

BlueNet Hospitals.